At Amphista Therapeutics we are developing drugs to bring life-changing medicines to patients. Powered by transformational science we are advancing beyond traditional degrader approaches.
A new approach to protein degradation
About us
Amphista Therapeutics is an exciting spin out company founded by Advent Life Sciences and built on groundbreaking science from the laboratory of Professor Alessio Ciulli (University of Dundee), a world leader in the field of targeted protein degradation.
Targeted Protein Degradation
Targeted protein degradation (TPD) hijacks the cell’s degradation machinery to modulate abundance of proteins that are responsible for disease progression. Our approach to protein degradation differentiates from traditional TPD technologies and is being developed to treat diseases with high unmet need.
Careers
Amphista is searching for innovative, and highly motivated individuals who enjoy teamwork and are comfortable working in a fast-paced entrepreneurial environment.
Drop us a line
We are here to answer any question you may have
Our Address
BioCity, Bo’Ness Rd, Newhouse, Chapelhall, Motherwell, ML1 5UH, UK
info@amphista.com
Registered Address
158-160 North Gower Street, London, England, NW1 2ND, UK
info@amphista.com
